Tags

Type your tag names separated by a space and hit enter

Prevention of urinary tract infections with vaccinium products.
Phytother Res 2014; 28(3):465-70PR

Abstract

Cranberries exert a dose-dependent inhibition of the adherence of E. coli fimbriae to uroepithelial cells. This was demonstrated in vitro but also ex vivo in vitro with urine from cranberry consumers. The active principle has not been identified in detail but type-A proanthocyanidins (PAC) play an important role in the mechanism of action. Since the three species, American cranberry (Vaccinium macrocarpon), European cranberry (Vaccinium oxycoccus) and/or lingonberry (Vaccinium vitis-idaea), have different patterns of type-A PACs, results from one species cannot be transferred to the others. It seems likely that most of the studies with monopreparations from V. macrocarpon were underdosed. Whereas photometric PAC quantification may overestimate the true content on co-active compounds, reversed phase high-performance liquid chromatograpy may underestimate them. Recent studies with PAC doses in the upper range (DMAC method) or declared type-A PAC content in the daily dose reveal a dose-dependent trend of clinical effectiveness, however, with a possible ceiling effect. In order to clarify this, future three-arm studies should investigate Vaccinium preparations with higher type-A PAC doses than previously used. We analysed two popular European vitis-idaea products, a mother juice and a proprietary extract. Both preparations may be appropriate to confirm the Vaccinium urinary tract infection-preventive effect beyond doubt.

Authors+Show Affiliations

Pain Relief Unit, Department of Anesthesia, Hadassah Hebrew University Hospital, Jerusalem, Israel.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23922238

Citation

Davidson, Elyad, et al. "Prevention of Urinary Tract Infections With Vaccinium Products." Phytotherapy Research : PTR, vol. 28, no. 3, 2014, pp. 465-70.
Davidson E, Zimmermann BF, Jungfer E, et al. Prevention of urinary tract infections with vaccinium products. Phytother Res. 2014;28(3):465-70.
Davidson, E., Zimmermann, B. F., Jungfer, E., & Chrubasik-Hausmann, S. (2014). Prevention of urinary tract infections with vaccinium products. Phytotherapy Research : PTR, 28(3), pp. 465-70. doi:10.1002/ptr.5047.
Davidson E, et al. Prevention of Urinary Tract Infections With Vaccinium Products. Phytother Res. 2014;28(3):465-70. PubMed PMID: 23922238.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevention of urinary tract infections with vaccinium products. AU - Davidson,Elyad, AU - Zimmermann,Benno F, AU - Jungfer,Elvira, AU - Chrubasik-Hausmann,Sigrun, Y1 - 2013/08/06/ PY - 2013/06/05/received PY - 2013/07/02/accepted PY - 2013/8/8/entrez PY - 2013/8/8/pubmed PY - 2014/5/27/medline KW - Vaccinium KW - cranberry KW - lingonberry KW - prevention KW - urinary tract infection SP - 465 EP - 70 JF - Phytotherapy research : PTR JO - Phytother Res VL - 28 IS - 3 N2 - Cranberries exert a dose-dependent inhibition of the adherence of E. coli fimbriae to uroepithelial cells. This was demonstrated in vitro but also ex vivo in vitro with urine from cranberry consumers. The active principle has not been identified in detail but type-A proanthocyanidins (PAC) play an important role in the mechanism of action. Since the three species, American cranberry (Vaccinium macrocarpon), European cranberry (Vaccinium oxycoccus) and/or lingonberry (Vaccinium vitis-idaea), have different patterns of type-A PACs, results from one species cannot be transferred to the others. It seems likely that most of the studies with monopreparations from V. macrocarpon were underdosed. Whereas photometric PAC quantification may overestimate the true content on co-active compounds, reversed phase high-performance liquid chromatograpy may underestimate them. Recent studies with PAC doses in the upper range (DMAC method) or declared type-A PAC content in the daily dose reveal a dose-dependent trend of clinical effectiveness, however, with a possible ceiling effect. In order to clarify this, future three-arm studies should investigate Vaccinium preparations with higher type-A PAC doses than previously used. We analysed two popular European vitis-idaea products, a mother juice and a proprietary extract. Both preparations may be appropriate to confirm the Vaccinium urinary tract infection-preventive effect beyond doubt. SN - 1099-1573 UR - https://www.unboundmedicine.com/medline/citation/23922238/Prevention_of_urinary_tract_infections_with_vaccinium_products_ L2 - https://doi.org/10.1002/ptr.5047 DB - PRIME DP - Unbound Medicine ER -